移植用HLAタイピングの世界市場予測:技術別(PCR(SSO、SSP、リアルタイム)、シークエンシング(NGS、サンガー))、製品別(装置、試薬、ソフトウェア)、用途別(キメラ現象、抗体スクリーニング)、エンドユーザー別(病院、診断ラボ、学界)

◆英語タイトル:HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) - Global Forecast to 2025
◆商品コード:BT 7584
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年3月30日
◆ページ数:194
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥691,600見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥847,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

MarketsandMarkets社は移植用HLAタイピングの世界市場が、2019年656百万ドルから2025年968百万ドルまで、年平均6.7%成長すると予測しています。本調査レポートでは、移植用HLAタイピングの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、製品&サービス別(試薬&消耗品、機器、ソフトウェア&サービス)分析、技術別(分子アッセイ技術、非分子アッセイ技術)分析、用途別(診断、研究)分析、エンドユーザー別(研究所、病院&移植センター、研究室、学術機関)分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・移植用HLAタイピングの世界市場:製品&サービス別(試薬&消耗品、機器、ソフトウェア&サービス)
・移植用HLAタイピングの世界市場:技術別(分子アッセイ技術、非分子アッセイ技術)
・移植用HLAタイピングの世界市場:用途別(診断、研究)
・移植用HLAタイピングの世界市場:エンドユーザー別(研究所、病院&移植センター、研究室、学術機関)
・移植用HLAタイピングの世界市場:地域別
・競争状況
・企業概要
【レポートの概要】

“The global HLA typing for transplants market is projected to grow at a CAGR of 6.7% during the forecast period.”
The global HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%. The demand for HLA typing products for transplant is expected to grow due to technological advancements in the field of HLA typing and increasing public-private funding for target research activities. The HLA typing for the transplants market is segmented on the product, technology, application, end-user, and region.

“The independent reference laboratories segment accounted for the largest share of the HLA typing for transplants market, by end-user, in 2019.”
Based on end user, the HLA typing for transplants market is segmented into independent reference laboratories, hospitals & transplant centers, and research laboratories & academic institutes. In 2019, independent reference laboratories accounted for the largest share of the HLA typing for transplants market due to rapid modernization and automation in diagnostic laboratories, the growing number of R&D activities outsourced by pharmaceutical & biotechnology companies to independent reference laboratories.

“The molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market, by technology, in 2019.”
The HLA typing for transplants market, by technology, is segmented into molecular (PCR-based assay and sequencing-based assay technologies) and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market due to the benefits of molecular assays such as low turnaround times, high procedural efficacy, and real-time sample analysis.

“North America accounted for the largest share of the HLA typing for transplants market in 2019.”
North America accounted for the largest share of the HLA typing for transplants market in 2019, followed by Europe. This can primarily be attributed to the wide availability of advanced transplant diagnostic technologies (includes HLA typing), well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for donors and recipients during transplantations.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
• By Designation: C-level (10%), Director-level (14%), and Others (76%)
• By Region: North America (40%), Europe (32%), APAC (20%), and RoW (8%)

Some of the prominent players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), and Omixon (Hungary).

Research Coverage
This report studies the HLA typing for transplants market based on product, technology, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It the the with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscapeusers emerging segments of the HLA typing for transplants market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

1 INTRODUCTION (Page No. – 21)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 24)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. – 33)

4 PREMIUM INSIGHTS (Page No. – 37)
4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW
4.2 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY
4.3 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION
4.4 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019
4.5 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE
4.6 HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY

5 MARKET OVERVIEW (Page No. – 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 KEY MARKET DRIVERS
5.2.1.1 Increasing number of transplant procedures
5.2.1.2 Technological advancements in the field of HLA typing
5.2.1.3 Increasing public-private funding for target research activities
5.2.2 KEY MARKET RESTRAINTS
5.2.2.1 High costs of molecular tests used for HLA typing procedures
5.2.2.2 Limited reimbursements for target procedures
5.2.3 KEY MARKET OPPORTUNITIES
5.2.3.1 Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation
5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling
5.2.3.3 Increasing public awareness about organ donation and transplantation across emerging countries
5.2.4 KEY MARKET CHALLENGES
5.2.4.1 Significant gap between the number of organ donors and organs required annually

6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE (Page No. – 50)
6.1 INTRODUCTION
6.2 REAGENTS & CONSUMABLES
6.2.1 INCREASING PATIENT EMPHASIS ON EFFECTIVE PATIENT PROFILING DURING ORGAN TRANSPLANTATION TO DRIVE MARKET GROWTH
6.3 INSTRUMENTS
6.3.1 INCREASING PATIENT AWARENESS ABOUT THE BENEFITS OFFERED BY GENOME-BASED PROFILING WILL SUPPORT MARKET GROWTH
6.4 SOFTWARE & SERVICES
6.4.1 RISING DEMAND FOR INNOVATIVE HLA TYPING SOFTWARE DURING THE DETECTION OF SPECIFIC ALLELES IS SUPPORTING MARKET GROWTH

7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY (Page No. – 55)
7.1 INTRODUCTION
7.2 MOLECULAR ASSAY TECHNOLOGIES
7.2.1 PCR-BASED MOLECULAR ASSAYS
7.2.1.1 Sequence-specific oligonucleotide-PCR
7.2.1.1.1 Growing awareness about the benefits offered by SSO-PCR among medical professionals to drive market growth
7.2.1.2 Sequence-specific primer-PCR
7.2.1.2.1 Growing public-private investments for research activities to support market growth
7.2.1.3 Real-time PCR
7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth
7.2.1.4 Other PCR-based molecular assays
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
7.2.2.1 Sanger sequencing
7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market growth
7.2.2.2 Next-generation sequencing
7.2.2.2.1 Expansion in the application horizons of NGS in the field of tissue typing to support market growth
7.2.2.3 Other sequencing-based molecular assays
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
7.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED HLA TYPING PROCEDURES IS EXPECTED TO HAMPER MARKET GROWTH

8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION (Page No. – 73)
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 ANTIBODY SCREENING
8.2.1.1 Rising number of recipients for transplant procedures to drive market growth
8.2.2 CHIMERISM MONITORING
8.2.2.1 Rising trend of personalized transplant medicine for effective post-procedural clinical risk management to drive market growth
8.2.3 OTHER APPLICATIONS
8.3 RESEARCH APPLICATIONS
8.3.1 INCREASING IDENTIFICATION OF NEW GENES & BIOMARKERS IN DONOR-RECIPIENT CROSS MATCH WILL DRIVE THE MARKET GROWTH

9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER (Page No. – 79)
9.1 INTRODUCTION
9.2 INDEPENDENT REFERENCE LABORATORIES
9.2.1 INCREASING NUMBER OF PREVENTIVE GENOMIC CLINICS TO DRIVE MARKET GROWTH
9.3 HOSPITALS & TRANSPLANT CENTERS
9.3.1 HEALTHCARE CONSOLIDATION AND ESTABLISHMENT OF NEW HOSPITALS TO SUPPORT MARKET GROWTH
9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
9.4.1 GROWING AWARENESS ABOUT THE RESEARCH APPLICATIONS IN TRANSPLANT REJECTION MONITORING TO DRIVE MARKET GROWTH

10 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION (Page No. – 84)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 Ongoing technological advancements in the field of HLA typing to drive market growth in the US
10.2.2 CANADA
10.2.2.1 Growing availability of HLA typing products to support market growth in Canada
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Germany accounted for the largest share of the European market
10.3.2 UK
10.3.2.1 Rising number of transplantation procedures to drive market growth in the UK
10.3.3 FRANCE
10.3.3.1 Adoption of molecular diagnostic techniques for donor-recipient compatibility testing is increasing in France
10.3.4 ITALY
10.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain market growth
10.3.5 SPAIN
10.3.5.1 Rising number of solid organ transplantation procedures to drive market growth in Spain
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.1.1 Significant growth in chronic disease prevalence to support market growth in Japan
10.4.2 CHINA
10.4.2.1 Healthcare infrastructure improvements to support market growth in China
10.4.3 INDIA
10.4.3.1 Increasing number of transplantation procedures to drive market growth in India
10.4.4 AUSTRALIA
10.4.4.1 Rising number of solid organ transplantation procedures to support market growth in Australia
10.4.5 SOUTH KOREA
10.4.5.1 Government initiatives to introduce medical coverage for transplantation to support market growth in South Korea
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Brazil accounted for the largest share of the LATAM market
10.5.2 MEXICO
10.5.2.1 Rising medical tourism to support market growth in Mexico
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE (Page No. – 130)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SCENARIO
11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS
11.3.2 KEY AGREEMENTS AND COLLABORATIONS
11.3.3 KEY ACQUISITIONS
11.3.4 KEY EXPANSIONS
11.4 COMPETITIVE LEADERSHIP MAPPING
11.4.1 VISIONARY LEADERS
11.4.2 INNOVATORS
11.4.3 DYNAMIC DIFFERENTIATORS
11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. – 136)
12.1 THERMO FISHER SCIENTIFIC
12.1.1 BUSINESS OVERVIEW
12.1.2 PRODUCTS OFFERED
12.1.3 RECENT DEVELOPMENTS (2015–2019)
12.1.4 RECENT DEVELOPMENTS (2015–2019)
12.2 F. HOFFMAN-LA ROCHE LIMITED
12.2.1 BUSINESS OVERVIEW
12.2.2 PRODUCTS OFFERED
12.3 QIAGEN
12.3.1 BUSINESS OVERVIEW
12.3.2 PRODUCTS OFFERED
12.3.3 RECENT DEVELOPMENTS (2015–2019)
12.3.4 MNM VIEW
12.4 IMMUCOR
12.4.1 BUSINESS OVERVIEW
12.4.2 PRODUCTS OFFERED
12.4.3 RECENT DEVELOPMENTS (2015–2019)
12.5 ABBOTT LABORATORIES INC.
12.5.1 BUSINESS OVERVIEW
12.5.2 PRODUCTS OFFERED
12.6 CAREDX, INC.
12.6.1 BUSINESS OVERVIEW
12.6.2 PRODUCTS OFFERED
12.6.3 RECENT DEVELOPMENTS (2016–2019)
12.7 ILLUMINA
12.7.1 BUSINESS OVERVIEW
12.7.2 PRODUCTS & SERVICES OFFERED
12.7.3 RECENT DEVELOPMENTS (2015–2019)
12.7.4 MNM VIEW
12.8 BIO-RAD LABORATORIES
12.8.1 BUSINESS OVERVIEW
12.8.2 PRODUCTS OFFERED
12.9 ALPHA BIOTECH, LTD.
12.9.1 BUSINESS OVERVIEW
12.9.2 PRODUCTS OFFERED
12.10 GENDX
12.10.1 BUSINESS OVERVIEW
12.10.2 PRODUCTS & SERVICES OFFERED
12.10.3 RECENT DEVELOPMENTS (2015–2019)
12.11 LUMINEX
12.11.1 BUSINESS OVERVIEW
12.11.2 PRODUCTS OFFERED
12.11.3 RECENT DEVELOPMENTS (2015–2019)
12.12 BIOFORTUNA
12.12.1 BUSINESS OVERVIEW
12.12.2 PRODUCTS OFFERED
12.12.3 RECENT DEVELOPMENTS (2015–2019)
12.13 OMIXON
12.13.1 BUSINESS OVERVIEW
12.13.2 PRODUCTS OFFERED
12.13.3 RECENT DEVELOPMENTS (2015–2019)
12.14 CREATIVE BIOLABS
12.14.1 BUSINESS OVERVIEW
12.14.2 PRODUCTS OFFERED
12.15 TBG DIAGNOSTICS LIMITED
12.15.1 BUSINESS OVERVIEW
12.15.2 PRODUCTS OFFERED
12.15.3 RECENT DEVELOPMENTS (2015–2019)
12.16 OTHER COMPANIES
12.16.1 BAG HEALTHCARE
12.16.2 TAKARA BIO
12.16.3 HISTOGENETICS LLC
12.16.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.5 HANSA BIOPHARMA AB

13 APPENDIX (Page No. – 180)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

LIST OF TABLES (141 Tables)

TABLE 1 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS FOR TRANSPLANT PROCEDURES, 2015–2018
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2017)
TABLE 3 APPLICABLE CODES FOR HLA TYPING
TABLE 4 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 5 REAGENTS & CONSUMABLES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 6 INSTRUMENTS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 7 SOFTWARE & SERVICES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 9 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 10 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 11 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 12 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 13 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 14 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 15 PCR-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 16 PCR-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 17 PCR-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 18 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 19 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 20 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 21 REAL-TIME PCR MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 22 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 23 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 24 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 25 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 26 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 27 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 28 SANGER SEQUENCING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 29 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 30 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 31 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 32 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 33 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 34 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 35 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 36 DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 37 DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 38 ANTIBODY SCREENING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 39 CHIMERISM MONITORING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 40 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 41 RESEARCH APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 43 INDEPENDENT REFERENCE LABORATORIES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 44 HOSPITALS & TRANSPLANT CENTERS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 45 RESEARCH LABORATORIES & ACADEMIC INSTITUTES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 47 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 48 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 49 NORTH AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 50 NORTH AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 54 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 55 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 56 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 57 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 58 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 59 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 60 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 61 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 62 EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 63 EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 67 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN GERMANY, 2015 VS. 2018
TABLE 68 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 71 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN THE UK, 2015 VS. 2018
TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 73 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 74 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 75 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN FRANCE, 2015 VS. 2018
TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 77 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 78 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 79 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN ITALY, 2015 VS. 2018
TABLE 80 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 81 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 82 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 83 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN SPAIN, 2015 VS. 2018
TABLE 84 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 85 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 86 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 87 ROE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 88 ROE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 89 ROE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 90 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 91 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 92 ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 93 ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 96 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 97 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 98 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 99 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 100 NUMBER OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CHINA, 2013 VS. 2015
TABLE 101 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 102 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 103 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 104 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN INDIA, 2015 VS. 2018
TABLE 105 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 106 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 107 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 108 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN AUSTRALIA, 2015 VS. 2018
TABLE 109 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 113 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 114 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 115 ROAPAC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 116 ROAPAC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 117 ROAPAC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 118 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 119 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 120 LATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 121 LATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 122 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 123 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 124 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 125 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN BRAZIL, 2015 VS. 2018
TABLE 126 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 127 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 128 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 129 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN MEXICO, 2015 VS. 2018
TABLE 130 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 131 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 132 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 133 ROLATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 134 ROLATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 135 ROLATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 136 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 137 MEA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 138 MEA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 139 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 140 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 141 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)

LIST OF FIGURES (36 Figures)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING FOR TRANSPLANTS MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE, 2019 VS. 2025
FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2019 VS. 2025 (USD MILLION)
FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2019 VS. 2025 (USD MILLION)
FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION)
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE HLA TYPING FOR TRANSPLANTS MARKET
FIGURE 11 INCREASING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
FIGURE 12 PCR-BASED MOLECULAR ASSAYS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
FIGURE 13 ANTIBODY SCREENING AND CHIMERISM MONITORING SEGMENTS TO WITNESS HIGH GROWTH IN THE ASIA PACIFIC MARKET
FIGURE 14 INDEPENDENT REFERENCE LABORATORIES ARE THE LARGEST END USERS IN THE APAC MARKET
FIGURE 15 NORTH AMERICA IS ESTIMATED TO BE THE LARGEST MARKET FOR ALL PRODUCT & SERVICE SEGMENTS IN THE HLA TYPING FOR TRANSPLANTS MARKET IN 2019
FIGURE 16 MARKET IN CHINA AND INDIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
FIGURE 19 SOLID ORGAN TRANSPLANTATIONS PERFORMED IN THE US, 2015–2019
FIGURE 20 SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CANADA, 2015–2018
FIGURE 21 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
FIGURE 22 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
FIGURE 23 NUMBER OF SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN JAPAN, 2015–2018
FIGURE 24 PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019
FIGURE 25 THERMO FISHER SCIENTIFIC DOMINATES THE GLOBAL HLA TYPING FOR TRANSPLANTS MARKET, AS OF 2019
FIGURE 26 HLA TYPING FOR TRANSPLANTS MARKET (GLOBAL): COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 27 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
FIGURE 28 F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018)
FIGURE 29 QIAGEN: COMPANY SNAPSHOT (2018)
FIGURE 30 IMMUCOR: COMPANY SNAPSHOT (2016)
FIGURE 31 ABBOTT LABORATORIES INC.: COMPANY SNAPSHOT (2018)
FIGURE 32 CAREDX: COMPANY SNAPSHOT (2018)
FIGURE 33 ILLUMINA: COMPANY SNAPSHOT (2018)
FIGURE 34 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018)
FIGURE 35 LUMINEX: COMPANY SNAPSHOT (2018)
FIGURE 36 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[移植用HLAタイピングの世界市場予測:技術別(PCR(SSO、SSP、リアルタイム)、シークエンシング(NGS、サンガー))、製品別(装置、試薬、ソフトウェア)、用途別(キメラ現象、抗体スクリーニング)、エンドユーザー別(病院、診断ラボ、学界)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆